12:00 AM
 | 
Apr 27, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ToleroMune cat allergy therapy: Phase II started

Circassia began a double-blind, placebo-controlled, Canadian Phase II trial to evaluate multiple doses of 3 nmol of intradermal ToleroMune in 48 patients with confirmed cat allergies...

Read the full 109 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >